ACE and Hypertension: For patients with new-onset VSPi-induced hypertension, the current guidelines recommend medications targeting the renin–angiotensin–aldosterone (RAAS) pathway such as ACE inhibitors, ARBs, and dihydropyridine CCBs as first-line therapy [30–32].